EMA Consults on Virtual Control Groups
The European Medicines Agency (EMA) is consulting on a new methodology involving virtual control groups in preclinical research. The approach aims to reduce the number of animals used in medicines development. The EMA's human medicines committee (CHMP) issued a draft qualification opinion on the methodology, seeking input from stakeholders. This initiative aligns with the EU's commitment to animal welfare and promotes innovative approaches in pharmaceutical research.
EMA consults on methodology to reduce animal use in medicine development.